Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion Refocuses on Immuno-Oncology; Q3 Loss $3.5M, Cash $13.3M to End-2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.54
Mkt Cap
$21.184M
52W Low
$2.425
52W High
$6.92
52W Position info
4.7% above low
Off High info
63% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

EVAX is trading near its 52-week low of $2.425 (4.7% above the low).

Summary

Evaxion is narrowing its pipeline to immuno-oncology, prioritizing off-the-shelf cancer vaccines EVX-04 and EVX-05, while reporting a $3.5 million Q3 net loss and $13.3 million in cash with runway into late 2027.


Key Events · Earnings and Guidance · EVAX

  • Strategy Refocused on Immuno-Oncology

    Evaxion will prioritize off-the-shelf cancer vaccines EVX-04 and EVX-05 and expand EVX-01 through partnerships, while infectious disease and autoimmune work proceeds only with external funding.

  • Q3 Net Loss of $3.5 Million

    No revenue was recorded in Q3 2026 versus $7.5 million a year earlier; R&D was $2.3 million and G&A $1.4 million, producing a $3.5 million net loss.

  • Cash Runway Extended to Late 2027

    Cash and equivalents were $13.3 million at September 30, 2026, down from $14.0 million at June 30, supported by $2.2 million of gross ATM proceeds.

  • Equity Falls to $8.1 Million

    Total equity dropped from $17.0 million at December 31, 2025 to $8.1 million at September 30, 2026, reflecting the $10.9 million nine-month net loss.


Analysis · EVAX · Life Sciences

Evaxion is dropping broad pipeline spending to concentrate on cancer vaccines, and the Q3 numbers show why: no revenue this quarter against a $3.5 million net loss, leaving $13.3 million of cash that management says funds operations into late 2027. That runway removes near-term financing pressure, but equity has fallen to $8.1 million from $17.0 million at the start of the year, and the ATM has already been used for $2.2 million of gross proceeds — so further share sales remain the likely funding path. The infectious disease programs now survive only with partner money, which puts the burden on business development rather than the balance sheet.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVAX was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $2.43 to $6.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Nov 19, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $2.54 info
Change: -$0.2794 (-10%) info
Market Cap: $21.184M info
EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.54 info
Change: -$1.50 (-37%) info
Market Cap: $21.184M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.54 info
Change: -$0.710 (-22%) info
Market Cap: $21.184M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.54 info
Change: -$0.930 (-27%) info
Market Cap: $21.184M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.54 info
Change: -$0.935 (-27%) info
Market Cap: $21.184M info